Moderna, Merck melanoma vaccine succeeds in Phase 3; shares surge up to 83%

MRK -0.29% BNTX -3.35% XBI -0.63% MS -1.20% PFE -0.64% 3 more

1. 1Moderna's shares jumped as much as 83% in pre-market trading on news of late-stage clinical success for its personalized melanoma vaccine developed with Merck
2. 2The combination of intismeran autogene and Keytruda improved recurrence-free survival versus Keytruda alone and also reduced the risk of metastasis
3. 3This marks the first Phase 3 positive result for a personalized cancer vaccine; exact figures have not been disclosed, and the earliest potential approval would come in 2027

Source Barrons.com +17 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →